Jean-Pierre Majoral

This inventor holds 9 USPTO granted patents and 1 published patent application, plus 2 CIPO patents and 5 EPO patents. Top assignees: Centre National De La Recherche Scientifique, Rhodia UK Limited, National Institute for Agricultural Research. Active years: 2005-2018.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Jean-Pierre Majoral. Retrieved from https://idiyas.com/inventor/jean-pierre-majoral

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 9 (Patent Applications = 1)

% Patents Active = 66.7

CIPO Patents = 2

EPO Patents = 5 (Patent Applications = 2)

Average Co-Inventor Count = 5.8

ph-index = 1

Forward Citations = 18(Granted Patents)

Location History:

Ramonville, FR (2005 - 2010)
Ramonville St Agne, FR (2010 - 2011)
Ramonville Saint-Agne, FR (2005 - 2018)

Company Filing History:

8 out of 5,383

Centre National De La Recherche Scientifique

National Institute for Agricultural Research

patents

4. 2 out of 1,853

National Institute of Health and Medical Research

patents

5. 1 out of 44

Aventis Cropscience S.a.

patents

6. 1 out of 113

Université De Rennes 1

patents

7. 1 out of 162

Université Paul Sabatier (Toulouse III)

patents

where one patent can have more than one assignee

Years Active: 2005-2018

Loading Chart...

9 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 10106565 - Phosphorylated dendrimers as antiinflammatory drugs (2018-10-23),

2. 8815834 - Use of dendrimers to stimulate cell growth (2014-08-26),

3. 8535643 - Flourescent dendrimer compounds and use of such compounds in multi-photon devices or processes (2013-09-17),

4. 8039580 - Dendritic polymers having monophosphonic terminations, method for preparing them, and their use (2011-10-18),

5. 7838625 - Dendritic polymers having biphosphonic terminations, derivatives thereof, method for preparing them, and their use (2010-11-23),

6. 7658946 - Solid supports functionalized with phosphorus-containing dendrimers, process for preparing them and uses thereof (2010-02-09),

7. 7517538 - Solid supports functionalised with phosphorus dendrimers, method for preparing same and uses thereof (2009-04-14),

8. 6969528 - Phosphorus-containing dendrimers as transfection agents (2005-11-29),

9. 6939831 - Pestcide and/or plant growth regulating compositions (2005-09-06),

Title: Jean-Pierre Majoral: Pioneer in Dendritic Polymer Chemistry

Introduction

Jean-Pierre Majoral is a notable inventor based in Ramonville, France, recognized for his significant contributions to dendritic polymer chemistry. With a portfolio of 9 patents, he has been instrumental in advancing the field of medicinal chemistry through innovative applications of dendrimers.

Latest Patents

Among his recent patents, Majoral has developed phosphorylated dendrimers as anti-inflammatory drugs. This invention focuses on dendrimers with monophosphonic or bisphosphonic terminations to treat inflammatory diseases. Another significant patent describes the use of dendrimers to stimulate cell growth, targeting monophosphonic or bisphosphonic terminations to enhance cell culture viability and activation.

Career Highlights

Jean-Pierre Majoral has held prestigious roles in renowned organizations, notably at the Centre National de La Recherche Scientifique (National Center for Scientific Research) and Rhodia UK Limited. His work in these institutions has paved the way for groundbreaking research and development in dendrimer applications.

Collaborations

Majoral’s collaborative efforts have included working alongside esteemed colleagues such as Anne-Marie Caminade and Laurent Griffe. These partnerships have enriched his research and contributed to the successful development of innovative dendrimer-based solutions.

Conclusion

Jean-Pierre Majoral’s contributions to the scientific community through his patents and collaborations showcase his prolific role as an inventor in the realm of dendritic polymers. His ongoing research promises to deliver further advancements in the treatment of inflammatory diseases and cellular growth stimulation, reinforcing his status as a leader in his field.

Profile summary based on public USPTO records.